29th August 2014, Barcelona, Spain
Members of the Editorial Board met to discuss the latest PCSK9 science and future research challenges. Presentations given by five Board Members focused on basic science and clinical perspectives.
PCSK9 and Lp(a), a novel approach to a re-emergent cardiovascular risk factor
Weighing the cost versus benefit of PCSK9-targeted therapy
High cholesterol: an unmet need
Looking ahead with PCSK9 Education & Research Forum
What are the patient priorities for PCSK9 inhibitors?
Does PCSK9 inhibition impact atherosclerosis?
Loss of function mutations in PCSK9: the trigger for therapeutic development
Does PCSK9 have effects beyond the liver and if so, what is the evidence?
Familial hypercholesterolaemia: putting the patient first
Going forward, a number of issues were identified:
- Elucidation of the underlying mechanism of PCSK9 inhibition in lowering Lp(a)
- In the identified patient priorities, would it be feasible to bypass other lipid-lowering therapies (after statins)? Is there a greater role for imaging in the management of these patients?
- Comprehensive evaluation of the benefit versus risk of these treatments in each clinical setting
- Education to minimise barriers to the use of PCSK9-targeted therapies (beyond cost).
- FH: to use a collaborative approach to educate clinicians about FH, so as to improve diagnosis and management
- Media support
- Patient-directed materials